ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and β-thalassemia
Recent News About FDA View More
SK LIFE SCIENCE, INC.: Announces FDA Acceptance of IND Application for Anti-Epileptic Drug Candidate SKL24741
Acceptance of the IND application will allow the company to begin Phase I clinical trials for SKL24741 in 2020
FDA Approves XCOPRI® (cenobamate tablets), an Anti-Epileptic Drug (AED) from SK Biopharmaceuticals, Co., Ltd., and U.S. Subsidiary SK Life Science, Inc.
XCOPRI is approved for the treatment of partial-onset seizures in adult patients